Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1 inhibitors

- PMLiVE

Merck suspends two Keytruda trials after patient deaths

Investigators to look at Keytruda with Pomalyst and Revlimid

Novartis building

Novartis’ Zykadia claims US approval for first-line lung cancer

The Swiss pharma giant’s drug also receives CHMP positive opinion

- PMLiVE

MSD probed by UK for blocking Remicade biosimilars

Pharma giant’s discount scheme for infliximab labelled ‘anti-competitive’

- PMLiVE

Keytruda is first FDA-approved drug for molecular indication

Indicates a significant development in the shift towards personalised medicine

- PMLiVE

Merck says Afferent’s chronic cough drug clears mid-stage trial

MK-7264 reduces coughs per hour by 37%

Novartis building

Novartis’ Zykadia prepped to take on Xalkori in Europe

The Swiss pharma giant’s drug will treat ALK-positive NSCLC patients

- PMLiVE

Merck takes on Roche with first-line bladder OK for Keytruda

FDA awards accelerated approval for mUC patients

- PMLiVE

Merck gains ground in lung cancer with first-line combo approval

Keytruda wins FDA backing for all first-line NSCLC patients

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

Bristol Myers Squibb logo

Apexigen and BMS team up for lung cancer immunotherapy trial

Opdivo and APX005M used together may improve immune reaction

National Institute for Health and Care Excellence NICE logo

NICE turns down Opdivo for head and neck cancer

BMS’s nivolumab proves too costly for the NHS

- PMLiVE

FDA won’t add outcomes data to Januvia label

Merck & Co’s application rejected despite TECOS outcomes data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links